{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:14:41Z","timestamp":1728360881736},"reference-count":12,"publisher":"Aerospace Medical Association","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["aerosp med hum perform"],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Graves\u2019 Disease (GD) is a common cause of hyperthyroidism. Although definitive treatment with radioactive iodine (RAI) is preferred for military aircrew, there are cultural and individual differences in receptivity toward RAI, and clinical guidelines that recommend\n antithyroid drugs (ATD) as the first line therapy. We examined a case series of Republic of Singapore Air Force (RSAF) aviators with GD treated with ATD and the impact of their condition on aeromedical disposition.<jats:bold>CASE SERIES:<\/jats:bold> All RSAF aircrew diagnosed with GD and treated with\n ATD over a 15-yr period were retrospectively identified and analyzed to determine the impact on their fitness for flying duties. The mean age of the 13 aircrew was 33 \u00b1 7.1 yr (range, 25\u201347 yr), with 11 (84.6%) being males. There were 10 (76.9%) who had ATD as the only treatment\n while 3 (23.1%) were initially treated with ATD but subsequently underwent RAI or surgery. Of the 10 treated with only ATD, 3 (30.0%) were returned to restricted flying, 6 (60.0%) were returned to unrestricted flying, and 1 (10.0%) is still undergoing ATD titration. There were 10 (76.9%) aircrew\n who were returned to some form of flying duties while on low doses of ATD.<jats:bold>DISCUSSION:<\/jats:bold> This case series suggests that ATD is a viable treatment modality in the aeromedical management of military aviators with GD and it is possible to return military aircrew on a stable maintenance\n dose of ATD to flying duties. A framework is proposed to support the aeromedical decision-making process for military aircrew in the treatment of GD.<jats:bold>Loh EH-T, Soh FW, See B, Tan BBC. <jats:italic>Aeromedical decision making for military aircrew with Graves\u2019 disease<\/jats:italic>. Aerosp Med Hum Perform.\n 2021; 92(12):980\u2013986.<\/jats:bold><\/jats:p>","DOI":"10.3357\/amhp.5885.2021","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T15:15:46Z","timestamp":1641482146000},"page":"980-986","source":"Crossref","is-referenced-by-count":0,"title":["Aeromedical Decision Making for Military Aircrew with Graves\u2019 Disease"],"prefix":"10.3357","volume":"92","author":[{"given":"Edwin Hong-Teck","family":"Loh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng Wei","family":"Soh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"See","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin Boon Chuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1911","reference":[{"issue":"24","key":"B1","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMcp0801880","article-title":"Clinical practice. Graves\u2019 disease","volume":"358","author":"Brent","year":"2008","journal-title":"N Engl J Med."},{"issue":"1","key":"B2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/thy.2019.0775","article-title":"Retrospective view of thyroid by its former editors","volume":"30","author":"Hershman","year":"2020","journal-title":"Thyroid."},{"issue":"10","key":"B3","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF03346433","article-title":"Long-term follow-up of patients with hyperthyroidism due to Graves\u2019 disease treated with Methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low Methimazole doses: a retrospective study","volume":"31","author":"Mazza","year":"2008","journal-title":"J Endocrinol Invest."},{"issue":"6","key":"B4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMct1007101","article-title":"Radioiodine therapy for hyperthyroidism","volume":"364","author":"Ross","year":"2011","journal-title":"N Engl J Med."},{"issue":"10","key":"B5","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid."},{"issue":"1","key":"B6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/ct.2020;32.9-11","article-title":"Most patients with Graves\u2019 disease treated with antithyroid drugs eventually require additional therapies","volume":"32","author":"Samuels","year":"2020","journal-title":"Clin Thyroidol."},{"issue":"9","key":"B7","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1210\/jc.2013-1954","article-title":"Comparative effectiveness of therapies for Graves\u2019 hyperthyroidism: a systematic review and network meta-analysis","volume":"98","author":"Sundaresh","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"B8","first-page":"2986","article-title":"Graves\u2019 hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine- a prospective, randomized study. Thyroid study group","volume":"81","author":"T\u00f6rring","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"key":"B9"},{"key":"B10"},{"issue":"4","key":"B11","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1210\/jc.2015-3644","article-title":"Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves\u2019 hyperthyroidism","volume":"101","author":"Vos","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"B12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1089\/thy.2011.2106.ed1","article-title":"The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines: viewpoints from Japan and Korea","volume":"21","author":"Yamashita","year":"2011","journal-title":"Thyroid."}],"container-title":["Aerospace Medicine and Human Performance"],"original-title":[],"link":[{"URL":"https:\/\/asma.kglmeridian.com\/view\/journals\/amhp\/92\/12\/article-p980.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/asma.kglmeridian.com\/downloadpdf\/journals\/amhp\/92\/12\/article-p980.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/asma.kglmeridian.com\/downloadpdf\/journals\/amhp\/92\/12\/article-p980.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:21:18Z","timestamp":1728303678000},"score":1,"resource":{"primary":{"URL":"https:\/\/asma.kglmeridian.com\/view\/journals\/amhp\/92\/12\/article-p980.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":12,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.3357\/amhp.5885.2021","relation":{},"ISSN":["2375-6314","2375-6322"],"issn-type":[{"type":"print","value":"2375-6314"},{"type":"electronic","value":"2375-6322"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}